Mark L Levitt
RedHill Biopharma Limited
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark L Levitt as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:54 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04502069 · Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring OxygenRedHill Biopharma Limited · withdrawn · COVID-19, Lung Infection · study director
- Ph2/Ph3NCT04467840 · Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 PneumoniaRedHill Biopharma Limited · completed · COVID-19, Lung Infection · study director
- Ph2NCT04414618 · A Study of Opaganib in Coronavirus Disease 2019 PneumoniaRedHill Biopharma Limited · completed · Coronavirus Infections · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:54 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer.Am J Clin Oncol · 199540 citationsRCR 0.8
- Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.Lung Cancer · 200424 citationsRCR 0.5
- 12 citationsRCR 0.2